Page 1216 - TNFlipTest

PS52 Psychiatry
References Toronto Notes 2019
• criteriaforaphysiciantoissueaCTO
■ patient with a prior history of hospitalization
■ a community treatment plan for the person has been made
■ examination by a physician within the previous 72 h before entering into the CTO plan
■ ability of the person subject to the CTO to comply with it
■ consultation with a rights advisor and consent of the person or the person’s substitute decision
maker
• CTOsarevalidfor6mounlesstheyarerenewedorterminatedatanearlierdatesuchas
■ where the person fails to comply with the CTO
■ when the person or his/her substitute decision-maker withdraws consent to the community
treatment plan
• CTOprocessisconsent-basedandallstatutoryprotectionsgoverninginformedconsentapply • therightsofapersonsubjecttoaCTOinclude
■ the right to a review by the Consent and Capacity Board with appeal to the courts each time a CTO is issued or renewed
■ a mandatory review by the Consent and Capacity Board every second time a CTO is renewed
■ the right to request a re-examination by the issuing physician to determine if the CTO is still
necessary for the person to live in the community
■ the right to review findings of incapacity to consent to treatment
■ provisions for rights advice
Duty to Inform/Warn
• seeEthical,Legal,andOrganizationalMedicine,ELOM6 References
Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatr 2010;22:417-28.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington: American Psychiatric Publishing, 2013.
American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5. Washington: American Psychiatric Publishing, 2013.
Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015 Dec 8;351:6019.
Avenevoli S, Swendsen J, He J et al. Major depression in national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. J Am Acad of Child Adolesc Psychiatry. 2015;54(1):37-44.e2.
Ball JR, Mitchell PB, Corry JC, et al. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiat 2006;67:277-86.
Black, Andreasen. Introductory Textbook of Psychiatry, 6th Edition. American Psychiatric Pub, 2014.
Caplan JP, Stern TA. Mnemonics in a mnutshell: 32 aids to psychiatric diagnosis. Current Psychiatry 2008;7(10):27.
Center for Substance Abuse Treatment. Treatment for Stimulant Use Disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999. (Treatment Improvement Protocol (TIP) Series, No. 33.) Chapter 2—How Stimulants Affect the Brain and Behavior. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK64328/.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 20. Pii: S0140-6736(17)32802-7.
Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull 2006;32:3-8.
Clinical Practice Guidelines: treatment of schizophrenia. Can J Psychiat 2005;50(Suppl1):19-28.
Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia, 1st ed. USA: Professional Communications, 2000.
Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012;26:155-83.
Ditto KE. SSRI discontinuation syndrome: awareness as an approach to prevention. Postgrad Med 2003;114:79-84.
Douglas J, Scott J. A systematic review of gender-specific rates of unipolar and bipolar disorders in community studies of pre-pubertal children. Bipolar Disord 2014;16(1):5-15. Firth J, Cotter J, Elliott R, et al. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 2015;45(7):1343-61.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
Fong, TG, Tulebaev SR, SK Inuoye. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neuro 2011;5(4):210-22.
Food and Drug Administration. Latuda (Lurasidone) NDA 200603 Approval Package. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2010/200603Orig1s000TOC.cfm. Accessed March 15, 2011.
Gliatto MF, Rai AK. Evaluation and treatment of patients with suicidal intention. Am Fam Physician 1999;59:1500-14.
Glick I, Murray S, Vasudevan P et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001:35(3):187-191.
Graham-Knight D, Karch AM. Pharm party. Am J Nurs 2007;107:79.
Grotenherman F. Pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2003;42(4):327-60.
Hembree EA, Foa EB. Post traumatic stress disorder: psychological factors and psychosocial interventions. J Clin Psychiat 2000;61(Suppl7):33-9.
Herrmann N. Recommendations for the management of behavioural and psychological symptoms of dementia. Can J Neurol Sci 2001;28(Suppl1):96-107.
Hetrick SE, McKenzie JE, Cox GR et al. Newer generation antidepressants for depressive disorders in children and adolescents. The Cochrane Database System Rev 2012;11:CD004851.
Hill, KP. (2015). Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA, 313(24), 2474-2483. Doi: 10.1001/ jama.2015.6199.
Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014 Jun 19;370(25):2397-407.
Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003;6(2):127-37.
Kahan M, Wilson L. Managing alcohol, tobacco and other drug problems: a pocket guide for physicians and nurses. Toronto: Centre for Addiction and Mental Health, 2002.
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiat 1999;156:286-93.
Kim SI, Swanson TA, Caplan JP, eds. Underground clinical vignettes step 2: psychiatry. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:130.
Koch T. A tour of the psychotropics, 4th ed. Toronto: Mental Health Service, St Michael’s Hospital.
Krupnick JL, Sotsky SM, Simmens S, et al. The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health treatment of depression collaborative research program. J Consult Clin Psychol 1996;64:532-39.
Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011;342:d738. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 2005;353:1209-23.
Lineham MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behaviour therapy vs. therapy by experts for suicidal behaviours and boderline personality disorder. Arch Gen Psychiat 2006;63:757-66.
Locher C, Koechlin H, Zion SR, et al. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2017 Oct 1;74(10):1011-1020
Lopez M, Torpac MG. The Texas children’s medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/ hyperactivity disorder. Part I. Am Acad Child Adolescent Psychiat 2000;39:908-19.
March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.